Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months

Kairos Pharma, LTD.

Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.
5 of 8 patients continuing without progression; 7 of 9 showed PSA decrease from baseline.
Trial powered for 45% PFS improvement; actual PFS far exceeded CARD trial benchmark of 3.7-6.7 months.
No Grade 3/4 toxicities observed; ENV105 well tolerated with standard supportive care.
Phase 2 trial enrolling at Cedars-Sinai, City of Hope, Huntsman Cancer Center; KOL event held Sept 18.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.